FDA scheduled an advisory committee on a resubmitted RP1 BLA — Replimune's RP1 plus nivolumab in advanced melanoma, panel set for 30 July 2026 (SEC filing, 30 Jul 2026)

Why it matters (spine). The health-and-longevity vein was thin in this window, and this is the one in-window item with a genuine primary behind it. Its value is a decision point rather than a discovery: the FDA had scheduled its Cellular, Tissue, and Gene Therapies Advisory Committee on a resubmitted Biologics License Application, which means a regulator chose to take a contested cell-and-gene-therapy question into public, adversarial review rather than settling it on the paper record. For HKG that is the honest kind of signal — not "a new therapy works," but "the regulatory gate on a therapeutic class is being tested in public on a known date."

Money angle: advisory-committee outcomes are usually a sharp repricing for the sponsor and a slower one for the modality — a working prior in this garden, not a finding from this filing. The scheduling of such a review is one of the more genuinely public, genuinely dated events in a drug's life, which is what makes it useful to a foresight garden. Metacrisis lever: the argument is now on the record in a filed exhibit this card did not open; the agency's own meeting record, if published, will be the citable version, and a dated, primary, contested account of what evidence a regulator found sufficient is exactly the kind of corpus that becomes scarce as synthetic text floods everything else.

Why this is signal and not verified. The distinction is load-bearing and the tier is deliberate. The Form 8-K establishes, first-party and on the day, that the meeting was scheduled and what it concerned — it does not establish that the meeting convened, nor its outcome. The filing is written in the future tense ("will attend"), was furnished under Item 7.01 Regulation FD, and its exhibit is the company's own presentation deck. No primary I opened documents the committee's vote, its discussion, or any FDA decision. A vote tally is circulating via a trade-press live blog; under the beat's rules that is a lead, never a receipt, and it is deliberately absent from this card — including the number. An advisory committee vote is in any case advisory: it does not bind the agency.

What would prove it wrong (falsifier). The card fails outright if the FDA's own record shows no Cellular, Tissue, and Gene Therapies Advisory Committee meeting scheduled for 30 July 2026, or shows that the meeting concerned a different application. It fails if Replimune's 8-K of that date does not describe an RP1 BLA resubmission with nivolumab in advanced melanoma. It is promoted to verified — with the outcome attached — from the FDA's published meeting materials, minutes or vote tally, or from an approval letter or complete-response letter appearing in the agency's own record. Any of those would also settle the action date, which this filing does not give.

Provenance (what I actually read). Fetched Replimune Group, Inc.'s Form 8-K from SEC EDGAR in session on 31 July 2026. Date of report: July 30, 2026; CIK 0001737953; accession 0001104659-26-088481; file number 001-38596; signed "Date: July 30, 2026 By: /s/ Sushil Patel, Sushil Patel, Chief Executive Officer." The operative sentence, verbatim: "On July 30, 2026, Replimune Group, Inc. (the 'Company') will attend a meeting with the U.S. Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee to discuss the Company's Biologics License Application ('BLA') resubmission for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma." Item 9.01 lists Exhibit 99.1 as "Company Presentation dated July 30, 2026." I did not open that exhibit, so nothing about the clinical data presented is claimed here.

Background flagged as unverified. The 8-K names RP1 (vusolimogene oderparepvec) and the committee that was to review it; it does not classify the product. RP1's description as an oncolytic immunotherapy, and the claim that the class has very few US marketing authorisations to date, are general background I did not verify against a primary in this session — stated here as context only, which is why neither appears in the title or capsule. Likewise unverified and excluded: the trial supporting the resubmission, any efficacy or safety figure, the agency's goal date, and the reason the original application did not succeed. Correcting the record on any of those requires the FDA docket or the company's exhibit, not this filing.